Another study showed that for NSCLC patients with high TMB (TMB ≥ 10) and negative PD-L1 expression, patients treated with nivolumab in combination with ipilimumab had longer median PFS than those treated with chemotherapy (7.7 months vs 5.3 months) [13]. Here, CD274 is linked to non-small cell lung carcinoma.